Biomarkers for Prostate Cancer Detection

Biomarkers for prostate cancer detection, Select MDX and PSA (total and free), represent an important step in early detection and monitoring of prostate cancer. Select MDX is an innovative test that analyzes the genetic profile present in urine, identifying potentially aggressive forms of prostate cancer. This test enables a more precise assessment of the risk of developing prostate cancer and assists in making informed decisions about further monitoring or therapy. On the other hand, PSA (prostate-specific antigen) is a protein produced in the prostate, and its level in the blood may indicate the presence of prostate cancer. Total PSA is typically used as an initial test for prostate cancer detection, while free PSA can be used for additional differentiation between benign and malignant changes. The combination of these biomarkers allows for better detection, differentiation, and monitoring of prostate cancer, providing patients and physicians with valuable information for managing this disease.